In summary, our findings suggest a reassuring safety profile when considering the application of SERPING1 overexpression for the future treatment of LC, with no substantial increase in cardiometabolic risks or susceptibility to cardiovascular diseases identified in our comprehensive assessment. This evidence concerns the gene SERPING1 and cardiovascular disorder.